 |
 |
Date Announced: 06 Aug 2013
Goldman Sachs-fueled leveraged buy-out for ophthalmology giant was first announced in May.
LAVAL, Quebec, Aug. 6, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the previously announced acquisition of Bausch + Lomb Holdings Incorporated.
Bausch + Lomb is a leading global eye health company that has a broad portfolio of eye health products, including well-known prescription and OTC brands Besivance, Lotemax, Ocuvite and PreserVision; vision care brands Biotrue ONEday, PureVision, renu and Boston; and surgical brands enVista, Storz, Stellaris and VICTUS.
Source: Valeant Pharmaceuticals
E-mail: via web site
Web Site: www.valeant.com
| © 2025 SPIE Europe |
|
